Skip to main content
. Author manuscript; available in PMC: 2014 May 2.
Published in final edited form as: Clin Cancer Res. 2012 Sep 17;18(21):6058–6064. doi: 10.1158/1078-0432.CCR-11-3251

Figure 1.

Figure 1

Average concentration × time curves for each dose level (mg/m2/dose). Plasma samples were obtained on cycle 1, day 1 for patients receiving once-daily dosing (45, 60, 80, and 100 mg/m2/dose) and twice-daily dosing (30 or 40 mg/m2/dose, twice daily). For patients receiving twice-daily dosing the second dose of MLN8237 on day 1 was not administered for accurate determination of pharmacokinetic parameters.